The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics

Why It Matters

Simultaneous triple‑target engagement promises to overcome tumor heterogeneity and resistance, expanding treatment options and creating a multi‑billion‑dollar growth opportunity for biopharma.

Key Takeaways

• Over 100 trispecific candidates are in clinical development worldwide
• Pfizer's tilrekimig met primary endpoint in phase 2 atopic dermatitis
• J&J's JNJ‑79635322 showed 86% response rate in multiple myeloma phase 1
• Fast‑track FDA designation granted to Innovent’s IBI3003 for multiple myeloma

Pulse Analysis

The rise of trispecific antibodies marks a logical evolution in antibody engineering, moving beyond the single‑target focus of monoclonal antibodies and the dual‑target approach of bispecifics. By binding three distinct antigens—often two tumor markers and a T‑cell engager—these molecules aim to improve tumor cell recognition, reduce antigen‑escape mechanisms, and fine‑tune immune activation. This added specificity is especially attractive for heterogeneous cancers and complex autoimmune pathways, where a single target may be insufficient to achieve durable responses.

Industry momentum has accelerated dramatically. In the past year, Pfizer, Sanofi, AbbVie and Johnson & Johnson each committed hundreds of millions of dollars to trispecific programs, reflecting confidence that the technology can translate early promise into commercial products. Notable data include Pfizer’s tilrekimig delivering a >75% reduction in eczema severity in a phase‑2 atopic dermatitis trial, and J&J’s JNJ‑79635322 achieving an 86% overall response rate in relapsed multiple myeloma with manageable toxicity. Meanwhile, innovators like Innovent and Excalipoint are securing fast‑track designations and seed financing to broaden the pipeline into solid tumors and rare indications. The primary challenge remains the intricate design and scalable manufacturing of these large, multi‑domain proteins, but recent advances in half‑life extension and modular platform technologies are mitigating those risks.

Looking ahead, analysts project the first trispecific approvals by 2028, mirroring the rapid adoption curve of bispecifics a decade earlier. Successful approvals could unlock a new class of high‑value biologics, offering clinicians a single‑molecule alternative to complex combination regimens. For investors and drug developers, the field represents a strategic frontier where precision immunotherapy meets commercial scalability, promising to reshape treatment paradigms across oncology, autoimmune disease, and potentially infectious disease as well.